Return to article

Trials Reference Year Published No. of Patients Interventions Large Published Trials Copenhagen Atrial Fibrillation, Aspirin, Anticoagulation I (AFASAK I) 468 1989 1,007 OA, ASA, placebo Copenhagen Atrial Fibrillation, Aspirin, Anticoagulation II (AFASAK II) 487 1998 677 OA, ASA, OA*+ASA, OA* Stroke Prevention in Atrial Fibrillation I (SPAF I) 32 1991 1,330 OA, ASA, placebo Stroke Prevention in Atrial Fibrillation II (SPAF II) 488 1994 1,100 OA, ASA Stroke Prevention in Atrial Fibrillation III (SPAF III) 438 1996 1,044 OA, OA*+ASA Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF) 456 1990 420 OA, control Canadian Atrial Fibrillation Anticoagulation (CAFA) 489 1991 378 OA, placebo Stroke Prevention in Nonrheumatic Atrial Fibrillation (SPINAF) 469 1992 571 OA, placebo European Atrial Fibrillation Trial (EAFT) 439 1993 1,007 OA, ASA, placebo Studio Italiano Fibrillazione Atriale (SIFA) 490 1997 916 OA, indobufen Minidose Warfarin in Nonrheumatic Atrial Fibrillation 491 1998 303 OA, OA* Prevention of Arterial Thromboembolism in Atrial Fibrillation (PATAF) 461 1999 729 OA, OA*, ASA Small or pilot trials Harenberg et al. 492 1993 75 LMW heparin, control Low-dose Aspirin, Stroke, Atrial Fibrillation (LASAF) 493 1996 285 ASA, placebo Subgroups with AF in other trials European Stroke Prevention Study II (ESPS II) 494 1997 429 ASA, dipyridamole, placebo Ongoing or unpublished AF trials French Aspirin Coumarin Collaborative Study ... ... OA, OA+ASA Swedish Atrial Fibrillation Trial ... ... ... Stroke Prevention using an Oral Thrombin Inhibitor in Atrial Fibrillation (SPORTIF) ... ... OA, thrombin inhibitor

AF indicates atrial fibrillation; OA, oral anticoagulation; OA

^* low-dose oral anticoagulation; ASA, aspirin; LMW, low-molecular-weight.

Adapted with permission from Hart et al. (460) Ann Intern Med 1999;131:492–501. (The American College of Physicians–American Society of Internal Medicine is not responsible for the accuracy of the translation.)

Return to article